Mean letter increase at 96 weeks was 7.6 letters in the group treated every 8 weeks with 2 mg of aflibercept, compared with 7.9 letters in the monthly ranibizumab group; 3-line VA increases were seen in 30%–33% for each arm of the study. OCT-measured anatomical response was maintained through 2 years with no significant difference in central retinal thickness among the 4 groups. Safety profiles were similar for both aflibercept and ranibizumab.